{
    "id": 29315,
    "fullName": "CCND1 Y44D",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CCND1 Y44D lies within cyclin N-terminal domain of the Ccnd1 protein (UniProt.org). Y44D results in increased protein levels relative to wild-type Ccnd1, increased protein stability as demonstrated by decreased phosphorylation of threonine-286, and nuclear localization, and has been associated with resistance to Imbruvica (ibrutinib) (PMID: 27713153).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 595,
        "geneSymbol": "CCND1",
        "terms": [
            "CCND1",
            "BCL1",
            "D11S287E",
            "PRAD1",
            "U21B31"
        ]
    },
    "variant": "Y44D",
    "createDate": "02/07/2019",
    "updateDate": "02/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 178232,
        "transcript": "NM_053056",
        "gDna": "chr11:g.69641443T>G",
        "cDna": "c.130T>G",
        "protein": "p.Y44D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Imbruvica (ibrutinib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Torkinib (PP242) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Zydelig (idelalisib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31315,
            "profileName": "CCND1 Y44D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178232,
            "transcript": "NM_053056",
            "gDna": "chr11:g.69641443T>G",
            "cDna": "c.130T>G",
            "protein": "p.Y44D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}